AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
Log in

NASDAQ:VBLTVascular Biogenics Stock Price, Forecast & News

$1.22
-0.01 (-0.81 %)
(As of 07/10/2020 10:00 AM ET)
Add
Compare
Today's Range
$1.21
Now: $1.22
$1.23
50-Day Range
$1.14
MA: $1.24
$1.39
52-Week Range
$0.90
Now: $1.22
$1.64
Volume26,829 shs
Average Volume653,615 shs
Market Capitalization$51.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.81
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Read More
Vascular Biogenics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
Phone972-8993-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$560,000.00
Book Value$1.00 per share

Profitability

Net Income$-19,460,000.00
Net Margins-2,909.45%

Miscellaneous

Employees38
Market Cap$51.16 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

How has Vascular Biogenics' stock been impacted by COVID-19 (Coronavirus)?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VBLT shares have increased by 0.0% and is now trading at $1.2201. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vascular Biogenics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vascular Biogenics.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Vascular Biogenics.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) announced its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The biopharmaceutical company had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.19 million. Vascular Biogenics had a negative return on equity of 53.61% and a negative net margin of 2,909.45%. View Vascular Biogenics' earnings history.

What price target have analysts set for VBLT?

4 brokers have issued 12-month target prices for Vascular Biogenics' stock. Their forecasts range from $2.50 to $5.00. On average, they anticipate Vascular Biogenics' share price to reach $3.88 in the next twelve months. This suggests a possible upside of 217.6% from the stock's current price. View analysts' price targets for Vascular Biogenics.

Has Vascular Biogenics been receiving favorable news coverage?

News coverage about VBLT stock has trended somewhat positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vascular Biogenics earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Vascular Biogenics.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a decrease in short interest in June. As of June 30th, there was short interest totaling 252,300 shares, a decrease of 10.8% from the June 15th total of 283,000 shares. Based on an average daily trading volume, of 613,700 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.8% of the shares of the stock are sold short. View Vascular Biogenics' Current Options Chain.

Who are some of Vascular Biogenics' key competitors?

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include Alibaba Group (BABA), Opko Health (OPK), SCYNEXIS (SCYX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), T2 Biosystems (TTOO) and AEterna Zentaris (AEZS).

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:
  • Prof. Dror Harats, CEO & Director (Age 63)
  • Mr. Amos Ron, CFO & Company Sec. (Age 65)
  • Dr. Erez Feige, VP of Bus. Operations (Age 46)
  • Dr. Eyal Breitbart, VP of Research & Operations (Age 53)
  • Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 66)

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.11%).

Which institutional investors are buying Vascular Biogenics stock?

VBLT stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc..

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.22.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $51.16 million and generates $560,000.00 in revenue each year. The biopharmaceutical company earns $-19,460,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.